Comments

Biogen

BIIBNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$226.40
1.150.51%
At Close: -
$226.40
00.00%
After Hours: Jul 19, 4:32 PM EDT
15 minutes delayed
Q2 2024 Earnings in 10 days from now on Thu Aug 1st, before the market open
Biogen (BIIB) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesGovernment TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$373.00
Lowest Price Target1
$200.00
Consensus Price Target1
$291.36

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Biogen (NASDAQ:BIIB) Stock, Analyst Ratings, Price Targets, Forecasts

Biogen Inc has a consensus price target of $291.36 based on the ratings of 25 analysts. The high is $373 issued by Morgan Stanley on November 10, 2023. The low is $200 issued by Barclays on April 25, 2024. The 3 most-recent analyst ratings were released by Piper Sandler, Needham, and RBC Capital on July 12, 2024, June 28, 2024, and June 27, 2024, respectively. With an average price target of $308 between Piper Sandler, Needham, and RBC Capital, there's an implied 36.04% upside for Biogen Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Mar
2
7
Apr
1
May
3
Jun
1
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.5
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler
Needham
RBC Capital
HC Wainwright & Co.
Truist Securities

1calculated from analyst ratings

Analyst Ratings for Biogen

Buy NowGet Alert
07/12/2024Buy Now38.25%Piper Sandler
Christopher Raymond
$335 → $313MaintainsOverweightGet Alert
06/28/2024Buy Now29.86%Needham
Ami Fadia
$294 → $294ReiteratesBuy → BuyGet Alert
06/27/2024Buy Now40.02%RBC Capital
Brian Abrahams
$317 → $317ReiteratesOutperform → OutperformGet Alert
06/26/2024Buy Now40.02%RBC Capital
Brian Abrahams
$317 → $317ReiteratesOutperform → OutperformGet Alert
06/05/2024Buy Now40.02%RBC Capital
Brian Abrahams
$317 → $317ReiteratesOutperform → OutperformGet Alert
05/29/2024Buy Now40.02%RBC Capital
Brian Abrahams
 → $317ReiteratesOutperform → OutperformGet Alert
05/23/2024Buy Now32.51%HC Wainwright & Co.
Andrew Fein
 → $300ReiteratesBuy → BuyGet Alert
05/22/2024Buy Now29.86%Needham
Ami Fadia
 → $294ReiteratesBuy → BuyGet Alert
05/16/2024Buy Now50.18%Truist Securities
Robyn Karnauskas
$340 → $340MaintainsBuyGet Alert
05/03/2024Buy Now51.06%HSBC
Morten Herholdt
$339 → $342MaintainsBuyGet Alert
04/29/2024Buy Now19.26%Oppenheimer
Jay Olson
$270 → $270MaintainsOutperformGet Alert
04/25/2024Buy Now29.86%Needham
Ami Fadia
 → $294ReiteratesBuy → BuyGet Alert
04/25/2024Buy Now-11.66%Barclays
Carter Gould
$215 → $200MaintainsEqual-WeightGet Alert
04/25/2024Buy Now-5.04%Wedbush
Laura Chico
$213 → $215MaintainsNeutralGet Alert
04/25/2024Buy Now32.51%HC Wainwright & Co.
Andrew Fein
$325 → $300MaintainsBuyGet Alert
04/24/2024Buy Now29.86%Needham
Ami Fadia
 → $294ReiteratesBuy → BuyGet Alert
04/19/2024Buy Now19.26%Oppenheimer
Jay Olson
$290 → $270MaintainsOutperformGet Alert
04/17/2024Buy Now-5.48%UBS
Colin Bristow
$250 → $214MaintainsNeutralGet Alert
04/17/2024Buy Now-5.92%Wedbush
Laura Chico
$245 → $213MaintainsNeutralGet Alert
04/12/2024Buy Now14.84%B of A Securities
Geoff Meacham
$280 → $260MaintainsNeutralGet Alert
04/11/2024Buy Now6.01%JP Morgan
Chris Schott
$270 → $240MaintainsNeutralGet Alert
04/04/2024Buy Now-5.04%Barclays
Carter Gould
$230 → $215MaintainsEqual-WeightGet Alert
03/25/2024Buy Now50.18%Truist Securities
Robyn Karnauskas
 → $340ReiteratesBuy → BuyGet Alert
03/05/2024Buy Now60.78%RBC Capital
Brian Abrahams
 → $364ReiteratesOutperform → OutperformGet Alert
02/22/2024Buy Now22.35%Mizuho
Salim Syed
$355 → $277MaintainsBuyGet Alert
02/20/2024Buy Now37.37%Cantor Fitzgerald
Eric Schmidt
 → $311ReiteratesOverweight → OverweightGet Alert
02/20/2024Buy Now34.72%Canaccord Genuity
Sumant Kulkarni
$310 → $305MaintainsBuyGet Alert
02/16/2024Buy Now10.42%UBS
Colin Bristow
$276 → $250MaintainsNeutralGet Alert
02/14/2024Buy Now39.58%Baird
Brian Skorney
$333 → $316MaintainsOutperformGet Alert
02/14/2024Buy Now43.55%Piper Sandler
Christopher Raymond
$350 → $325MaintainsOverweightGet Alert
02/14/2024Buy Now25.88%BMO Capital
Evan Seigerman
$295 → $285MaintainsOutperformGet Alert
02/14/2024Buy Now28.09%Oppenheimer
Jay Olson
$295 → $290MaintainsOutperformGet Alert
02/14/2024Buy Now60.78%RBC Capital
Brian Abrahams
$379 → $364MaintainsOutperformGet Alert
02/14/2024Buy Now6.01%Wells Fargo
Mohit Bansal
$315 → $240DowngradeOverweight → Equal-WeightGet Alert
02/14/2024Buy Now43.55%HC Wainwright & Co.
Andrew Fein
 → $325ReiteratesBuy → BuyGet Alert
02/14/2024Buy Now32.51%Needham
Ami Fadia
$305 → $300MaintainsBuyGet Alert
02/13/2024Buy Now34.72%Needham
Ami Fadia
 → $305ReiteratesBuy → BuyGet Alert
01/30/2024Buy Now30.3%Oppenheimer
Jay Olson
 → $295ReiteratesOutperform → OutperformGet Alert
01/25/2024Buy Now21.91%UBS
Colin Bristow
$311 → $276DowngradeBuy → NeutralGet Alert
01/24/2024Buy Now21.91%UBS
Colin Bristow
 → $276DowngradeBuy → NeutralGet Alert
12/20/2023Buy Now37.37%Cantor Fitzgerald
Eric Schmidt
 → $311ReiteratesOverweight → OverweightGet Alert
12/18/2023Buy Now30.3%Oppenheimer
Jay Olson
$280 → $295MaintainsOutperformGet Alert
12/14/2023Buy Now26.77%Stifel
Paul Matteis
$315 → $287MaintainsBuyGet Alert
12/07/2023Buy Now25%Raymond James
Danielle Brill
 → $283UpgradeMarket Perform → OutperformGet Alert
11/10/2023Buy Now64.75%Morgan Stanley
Matthew Harrison
$361 → $373MaintainsOverweightGet Alert
11/09/2023Buy Now30.3%BMO Capital
Evan Seigerman
$314 → $295MaintainsOutperformGet Alert
11/09/2023Buy Now60.34%RBC Capital
Brian Abrahams
$351 → $363MaintainsOutperformGet Alert
11/09/2023Buy Now5.57%Wedbush
Laura Chico
$266 → $239MaintainsNeutralGet Alert
11/09/2023Buy Now61.22%Wells Fargo
Mohit Bansal
$343 → $365MaintainsOverweightGet Alert
10/26/2023Buy Now17.49%Wedbush
Laura Chico
$270 → $266MaintainsNeutralGet Alert
10/26/2023Buy Now34.72%Needham
Ami Fadia
 → $305ReiteratesBuy → BuyGet Alert
10/11/2023Buy Now59.45%Morgan Stanley
Matthew Harrison
$381 → $361MaintainsOverweightGet Alert
09/06/2023Buy Now59.01%HSBC
Morten Herholdt
 → $360Initiates → BuyGet Alert
09/05/2023Buy Now68.29%Morgan Stanley
Matthew Harrison
$363 → $381MaintainsOverweightGet Alert
08/29/2023Buy Now57.69%RBC Capital
Brian Abrahams
$354 → $357MaintainsOutperformGet Alert
08/14/2023Buy Now47.97%Mizuho
Salim Syed
$340 → $335MaintainsBuyGet Alert
08/08/2023Buy Now50.18%Truist Securities
Robyn Karnauskas
$350 → $340MaintainsBuyGet Alert
08/08/2023Buy Now48.41%BMO Capital
Evan Seigerman
$347 → $336MaintainsOutperformGet Alert
08/08/2023Buy Now29.86%Barclays
Carter Gould
$311 → $294MaintainsEqual-WeightGet Alert
08/08/2023Buy Now34.72%Needham
Ami Fadia
$323 → $305MaintainsBuyGet Alert
08/08/2023Buy Now21.47%Atlantic Equities
Steve Chesney
$282 → $275MaintainsNeutralGet Alert
08/07/2023Buy Now56.36%RBC Capital
Brian Abrahams
$374 → $354MaintainsOutperformGet Alert
08/07/2023Buy Now28.09%Oppenheimer
Jay Olson
$360 → $290MaintainsOutperformGet Alert
08/07/2023Buy Now51.5%Wells Fargo
Mohit Bansal
$350 → $343MaintainsOverweightGet Alert
07/31/2023Buy Now65.19%RBC Capital
Brian Abrahams
$379 → $374MaintainsOutperformGet Alert
07/31/2023Buy Now42.67%Needham
Ami Fadia
 → $323ReiteratesBuy → BuyGet Alert
07/27/2023Buy Now44.43%Scotiabank
George Farmer
 → $327Initiates → Sector OutperformGet Alert
07/26/2023Buy Now60.34%Morgan Stanley
Matthew Harrison
$355 → $363MaintainsOverweightGet Alert
07/26/2023Buy Now67.4%RBC Capital
Brian Abrahams
$341 → $379MaintainsOutperformGet Alert
07/26/2023Buy Now18.37%Wedbush
Laura Chico
$269 → $268MaintainsNeutralGet Alert
07/26/2023Buy Now53.27%BMO Capital
Evan Seigerman
$357 → $347MaintainsOutperformGet Alert
07/26/2023Buy Now43.55%HC Wainwright & Co.
Andrew Fein
 → $325ReiteratesBuy → BuyGet Alert
07/26/2023Buy Now42.67%Needham
Ami Fadia
$320 → $323MaintainsBuyGet Alert
07/25/2023Buy Now41.34%Stifel
Paul Matteis
$324 → $320MaintainsBuyGet Alert
07/25/2023Buy Now41.34%Needham
Ami Fadia
 → $320ReiteratesBuy → BuyGet Alert
07/11/2023Buy Now56.8%Morgan Stanley
Matthew Harrison
$371 → $355MaintainsOverweightGet Alert
07/11/2023Buy Now50.62%RBC Capital
Brian Abrahams
$332 → $341MaintainsOutperformGet Alert
07/07/2023Buy Now43.55%HC Wainwright & Co.
Andrew Fein
 → $325ReiteratesBuy → BuyGet Alert
07/07/2023Buy Now41.78%Needham
Ami Fadia
 → $321ReiteratesBuy → BuyGet Alert
06/12/2023Buy Now59.01%Oppenheimer
Jay Olson
$350 → $360MaintainsOutperformGet Alert
06/12/2023Buy Now54.59%Canaccord Genuity
Sumant Kulkarni
$330 → $350MaintainsBuyGet Alert
06/12/2023Buy Now41.78%Needham
Ami Fadia
 → $321ReiteratesBuy → BuyGet Alert
06/12/2023Buy Now43.55%HC Wainwright & Co.
Andrew Fein
 → $325ReiteratesBuy → BuyGet Alert
06/08/2023Buy Now—Barclays
Carter Gould
—MaintainsOverweightGet Alert
06/08/2023Buy Now41.78%Needham
Ami Fadia
 → $321ReiteratesBuy → BuyGet Alert
06/07/2023Buy Now50.18%Baird
Brian Skorney
 → $340ReiteratesOutperform → OutperformGet Alert
06/02/2023Buy Now50.18%RBC Capital
Brian Abrahams
 → $340ReiteratesOutperform → OutperformGet Alert
06/01/2023Buy Now59.01%Piper Sandler
Christopher Raymond
$346 → $360MaintainsOverweightGet Alert
05/23/2023Buy Now16.17%Wedbush
Laura Chico
 → $263ReiteratesNeutral → NeutralGet Alert
05/11/2023Buy Now54.59%Argus Research
Jasper Hellweg
$320 → $350MaintainsBuyGet Alert
05/04/2023Buy Now41.34%B of A Securities
Geoff Meacham
$300 → $320MaintainsNeutralGet Alert
05/01/2023Buy Now54.59%Guggenheim
Yatin Suneja
$270 → $350UpgradeNeutral → BuyGet Alert
04/26/2023Buy Now45.76%Canaccord Genuity
Sumant Kulkarni
$325 → $330MaintainsBuyGet Alert
04/26/2023Buy Now50.18%RBC Capital
Brian Abrahams
$344 → $340MaintainsOutperformGet Alert
04/26/2023Buy Now16.17%Wedbush
Laura Chico
 → $263Reiterates → NeutralGet Alert
04/26/2023Buy Now43.55%Oppenheimer
Jay Olson
$310 → $325MaintainsOutperformGet Alert
04/26/2023Buy Now43.55%HC Wainwright & Co.
Andrew Fein
 → $325Reiterates → BuyGet Alert
04/26/2023Buy Now33.39%Barclays
Carter Gould
$307 → $302MaintainsEqual-WeightGet Alert
04/26/2023Buy Now41.78%Needham
Ami Fadia
$325 → $321MaintainsBuyGet Alert
04/26/2023Buy Now63.87%Morgan Stanley
Matthew Harrison
$349 → $371MaintainsOverweightGet Alert

FAQ

Q

What is the target price for Biogen (BIIB) stock?

A

The latest price target for Biogen (NASDAQ:BIIB) was reported by Piper Sandler on July 12, 2024. The analyst firm set a price target for $313.00 expecting BIIB to rise to within 12 months (a possible 38.25% upside). 75 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Biogen (BIIB)?

A

The latest analyst rating for Biogen (NASDAQ:BIIB) was provided by Piper Sandler, and Biogen maintained their overweight rating.

Q

When was the last upgrade for Biogen (BIIB)?

A

The last upgrade for Biogen Inc happened on December 7, 2023 when Raymond James raised their price target to $283. Raymond James previously had a market perform for Biogen Inc.

Q

When was the last downgrade for Biogen (BIIB)?

A

The last downgrade for Biogen Inc happened on February 14, 2024 when Wells Fargo changed their price target from $315 to $240 for Biogen Inc.

Q

When is the next analyst rating going to be posted or updated for Biogen (BIIB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biogen was filed on July 12, 2024 so you should expect the next rating to be made available sometime around July 12, 2025.

Q

Is the Analyst Rating Biogen (BIIB) correct?

A

While ratings are subjective and will change, the latest Biogen (BIIB) rating was a maintained with a price target of $335.00 to $313.00. The current price Biogen (BIIB) is trading at is $226.40, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch